“We are as an industry totally disappointed by the government’s decision.”
In a phone interview with CTVNews.ca, François Limoges, a spokesperson for the Quebec Cannabis Industry Association, voiced his organization’s displeasure with the Quebec government’s recent passing of a bill that raises the legal age to purchase cannabis. Starting Jan. 1, 2020, customers must be 21 years old to purchase cannabis in La Belle Province. Source: CTVNews.ca
“There are tons of ways to lose at this game … And everybody, I think, found that out this year.”
Ruston Peterson from Annabella, Utah, was among the first crop of farmers in the state to learn that growing hemp isn’t as easy as advertised, especially when there are so many unscrupulous businesses ready to take advantage of less-informed startups. Source: The Salt Lake Tribune
“While it was always understood that not every applicant would get a license, it is paramount that the application process have the utmost integrity, be transparent, and fair.”
In a letter to the Department of Cannabis Regulation, Los Angeles Council President Herb Wesson called on the city’s cannabis regulatory body to suspend the approval of new dispensaries, refund the latest round of cannabis applicants and conduct an independent audit after the department confirmed that some applicants had mistakenly received early access to the application page ahead of its official launch time. Wesson called the entire licensing process “compromised.” Source: Herb Wesson’s Office
“… the notion that revenue from the taxation of medical marijuana can be ‘transformational’ for state budgets is misplaced, though that may not be the case for recreational marijuana.”
In a report titled “Clearing the Air: What Can Wisconsin Learn From Medical Marijuana Laws in Other States?,” the Wisconsin Policy Forum, a statewide nonpartisan, independent policy research organization, concluded that taxpayers should temper their expectations that medical cannabis legalization would lead to a tax revenue boom, citing lower sales figures in medical markets and “the recognition that high taxes are arguably less justifiable for a substance used for medical purposes.” Source: Wisconsin Policy Forum
